SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$183M
Q3 2021
Positions
17
Filings on Record
15
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Consonance Capital Management LP reported $183M in U.S.-listed holdings across 17 positions for Q3 2021.

The portfolio is heavily concentrated: TNDM alone accounts for 31.8% of reported value.

Compared with Q2 2021, the fund opened 4 new positions and exited 19.

Portfolio Metrics

Turnover
+2.7%
vs prior filed quarter
Top-10 Concentration
+95.5%
share of reported value
Largest Position
+31.8%
Tandem Diabetes Care
New / Exited
4 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 84.1%Other: 13.6%ADR: 2.0%Equity WRT: 0.2%
  • Common Stock · 84.1% · $154M
  • Other · 13.6% · $25M
  • ADR · 2.0% · $4M
  • Equity WRT · 0.2% · $361,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SURROZEN INCNEW+1.00M1.00M+$7M$7M
ARYA SCIENCES ACQUISITN CORPNEW+300.0K300.0K+$3M$3M
OLINK HLDG ABNEW+115.4K115.4K+$3M$3M
SRZNWSURROZEN INCNEW+333.3K333.3K+$361,000$361,000
PTGXPROTAGONIST THERAPEUTICS INCSOLD OUT−3.45M0−$155M$0
LEGNLEGEND BIOTECH CORPSOLD OUT−1.65M0−$68M$0
VERASTEM INCSOLD OUT−13.60M0−$55M$0
KROSKEROS THERAPEUTICS INCSOLD OUT−887.9K0−$38M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

15 positions (from 17 filing rows — )
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TNDMTANDEM DIABETES CARE INChistory →COM NEW31.84%$58M487.3K
2GMEDGLOBUS MED INChistory →CL A24.71%$45M589.1K
3UTHRUNITED THERAPEUTICS CORP DELhistory →COM15.95%$29M157.8K
4SPRINGWORKS THERAPEUTICS INCCOM10.63%$19M306.0K
5SRZNWSURROZEN INCCOM · *W EXP 08/01/2033.87%$7M1.33M
6SLNSILENCE THERAPEUTICS PLChistory →ADS2.04%$4M178.8K
7ARYA SCIENCES ACQUISITN CORPCLASS A ORD SHS1.62%$3M300.0K
8RESEARCH ALLIANCE CORP IICOM CL A1.62%$3M300.0K
9MEDICUS SCIENCES ACQUISITIONCL A SHS · *W EXP 02/12/2021.61%$3M333.3K
10JIYA ACQUISITION CORPCOM CL A1.60%$3M300.0K
11OLINK HLDG ABSPONSORED ADS1.53%$3M115.4K
12PANACEA ACQUISITION CORP IICL A SHS1.07%$2M200.0K
13CASI PHARMACEUTICALS INCCOM1.02%$2M1.56M
14HELIX ACQUISITION CORPCOM CL A0.82%$1M150.0K
15CAREMAX INC*W EXP 06/08/2020.07%$134,00046.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.